GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » Price-to-Owner-Earnings

Quest PharmaTech (TSXV:QPT) Price-to-Owner-Earnings : (As of Jun. 04, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech Price-to-Owner-Earnings?

As of today (2024-06-04), Quest PharmaTech's share price is C$0.02. Quest PharmaTech does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Quest PharmaTech's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Quest PharmaTech was 50.00. The lowest was 10.00. And the median was 13.33.


TSXV:QPT's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.035
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-04), Quest PharmaTech's share price is C$0.02. Quest PharmaTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was C$-0.12. Therefore, Quest PharmaTech's PE Ratio for today is At Loss.

As of today (2024-06-04), Quest PharmaTech's share price is C$0.02. Quest PharmaTech's EPS without NRI for the trailing twelve months (TTM) ended in was C$-0.11. Therefore, Quest PharmaTech's PE Ratio without NRI for today is At Loss.

During the past 13 years, Quest PharmaTech's highest PE Ratio without NRI was 25.00. The lowest was 0.00. And the median was 8.00.


Quest PharmaTech Price-to-Owner-Earnings Historical Data

The historical data trend for Quest PharmaTech's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest PharmaTech Price-to-Owner-Earnings Chart

Quest PharmaTech Annual Data
Trend Jan14 Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.17 - -

Quest PharmaTech Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Quest PharmaTech's Price-to-Owner-Earnings

For the Biotechnology subindustry, Quest PharmaTech's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quest PharmaTech's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quest PharmaTech's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Quest PharmaTech's Price-to-Owner-Earnings falls into.



Quest PharmaTech Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Quest PharmaTech's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.02/-0.13
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quest PharmaTech  (TSXV:QPT) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Quest PharmaTech Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Quest PharmaTech (TSXV:QPT) Business Description

Traded in Other Exchanges
N/A
Address
8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4
Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.
Executives
Ragupathy Madiyalakan Director

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines